2. Academic Validation
  3. Establishment of Patient-derived Preclinical Models for Invasive Papillary Cholangiocarcinoma

Establishment of Patient-derived Preclinical Models for Invasive Papillary Cholangiocarcinoma

  • Anticancer Res. 2022 Jan;42(1):599-608. doi: 10.21873/anticanres.15517.
Benjamin Mwesige 1 2,  Mi Rim Lee 1 2,  Yu-Sun Lee 2 3,  Na Young Han 4,  Ji Eun Im 2,  Joon-Ki Kim 2,  Sun Il Choi 2,  En Kyung Hong 4,  A-Ra Jeon 2,  Sang-Jae Park 5,  Sang Myung Woo 6 5,  Yun-Hee Kim 6 2
Affiliations

Affiliations

  • 1 Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea.
  • 2 Division of Convergence Technology, Research Institute of National Cancer Center, Goyang, Republic of Korea.
  • 3 Department of Basic Biomedical, Kyung Hee University, Seoul, Republic of Korea.
  • 4 Department of Pathology, National Cancer Center, Goyang, Republic of Korea.
  • 5 Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Republic of Korea.
  • 6 Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea [email protected] [email protected].
PMID: 34969769 DOI: 10.21873/anticanres.15517
Abstract

Background/aim: Invasive papillary cholangio-carcinoma (IPC) is a minor subtype of extrahepatic cholangiocarcinoma. However, its etiology and characteristics remain unknown because of the unavailability of in vitro and in vivo models. We aimed to establish a novel preclinical model for translational research of IPC.

Materials and methods: A patient-derived xenograft (PDX) was engrafted in NOG mice and the cell line National Cancer Center human IPC (NCChIPC) was subsequently established from the PDX tumors. Immunohistochemistry and RNA-sequencing were used to determine the retention of original characteristics of patient tissues.

Results: PDX tumors showed successful amplification, and the NCChIPC-derived xenograft largely retained the histopathological features of the original tumor with CK19, MUC1 and MUC5AC expression. Transcriptome analysis showed a high correlation between patient and preclinical models. Additionally, Anticancer drugs response was analyzed in the NCChIPC PDX.

Conclusion: These novel preclinical models here will help elucidate IPC etiology and facilitate translational research.

Keywords

Invasive papillary cholangiocarcinoma; patient-derived xenograft; preclinical model.

Figures
Products